Introduction
TNBC, breast cancers, tumor
TUMOR, BREAST CANCER, TRIPLE-NEGATIVE BREAST CANCER, ATAXIA TELANGIECTASIA, METASTATIC DISEASE
Approximately 10% to 15% of breast cancers do not express hormone receptors [estrogen receptor (ER) or progesterone receptor (PgR)] and are HER2-negative. This triple-negative breast cancer (TNBC) subgroup has a poor prognosis with overall survival for those patients with metastatic disease of 1 to 2 years (AZD6738 (cerelasertib) is a potent, selective inhibitor of the serine/threonine-specific protein kinase, ataxia telangiectasia and Rad3-related (ATR) protein. ATR is an apical kinase in one of the DNA-damage induced checkpoint pathways (The plasmaMATCH trial was an open label, non-randomized, phase IIa clinical trial platform, consisting of circulating tumor DNA (ctDNA) testing in patients with advanced breast cancer linked to parallel treatment cohorts with therapies matched to mutations identified in ctDNA. The ctDNA screening component of the trial and Cohorts A–D have already been reported (